STSA IPOs 6.33M* shares @$15.00: https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-inc-announces-pricing-of-initial-public-offering-of-common-stock-300917583.html Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the pricing of its initial public offering… *Assuming exercise of underwriter’s option.